Çocuklarda Ağır Astım, Biyolojik Tedaviler ve Covid-19 Pandemisinde Güncel Yaklaşımlar

Ayşegül Ertuğrul; İlknur Bostancı

doi:10.12956/tchd.758127

Review

Çocuklarda Ağır Astım, Biyolojik Tedaviler ve Covid-19 Pandemisinde Güncel Yaklaşımlar

Year 2021, Volume: 15 Issue: 2, 168 - 173, 30.03.2021

Ayşegül Ertuğrul İlknur Bostancı

https://doi.org/10.12956/tchd.758127

Cited By: 2

Abstract

Astım, çocukluk çağında gözlenen en sık kronik hastalıktır. Ağır astım, çocuklarda daha nadir görülen bir durumdur. Ağır astımda farklı mekanizmalar rol oynadığı için farklı fenotipler söz konusu olup tedavi hastaya göre kişiselleştirilmelidir. Hastanın ağır astım fenotipine katkıda bulunan faktörlerin değerlendirilmesi sonucunda, tip 2 astım olduğu belirlenen hastalara biyolojik tedavilerin uygulaması günümüzde ağır astım tedavisi yönetiminde önemli bir gelişme sağlamıştır. COVID-19 pandemisi sırasında güncel rehberler, biyolojik ajan uygunluk kriterlerini karşılayan ve bu tedavilerin etkili olduğu hastalarda biyolojik tedavilerin uygulanmasına devam edilmesini önermektedir. Aktif SARS-CoV-2 enfeksiyonu durumunda klinik düzelme sağlanana kadar biyolojik tedavi durdurulmalıdır.

Keywords

ağır astım, biyolojikler, ÇOCUK, COVID-19

Supporting Institution

YOK

Project Number

YOK

Thanks

References

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259. doi:10.1016/S0140-6736(17)32154-2
2. National Survey of Children's Health. NSCH 2011/12. Data query from the Child and Adolescent Health Measurement Initiative, Data Resource Center for Child and Adolescent Health website. Available from: https://www.childhealthdata.org/learn-about-the-nsch/NSCH. Aaccessed 23 June 2020.
3. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health Interview Survey, 2016. Analysis by the American Lung Association Epidemiology and Statistics Unit using SPSS software. Available from: https://www.cdc.gov/nchs/nhis/methods.htm. Aaccessed 23 June 2020.
4. Ahmed H, Turner S. Severe asthma in children-a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019;54(6):778‐787. doi:10.1002/ppul.24317
5. Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U‐BIOPRED cohorts. EurRespir J. 2015;46:1322‐1333.doi:10.1183/13993003.00780-2015
6. Selby L, Saglani S. Severe asthma in children: therapeutic considerations. Curr Opin Allergy Clin Immunol. 2019;19(2):132-140. doi:10.1097/ACI.0000000000000521
7. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013.
8. 2020 GINA Maın Report. 2020 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org/gina-reports/. Aaccessed 23 June 2020.
9. Diffucult-to-treat and severe asthma in adolescent and adult patients Diagnosis and Management. GINA 2019. Available from: https://ginasthma.org/severeasthma/. Aaccessed 23 June 2020.
10. Nordlund B, Melen E, Schultz ES, Gronlund H, Hedlin G, Kull I. Prevalence of severe childhood asthma according to the WHO. Respir Med. 2014;108:1234‐1237. doi:10.1016/j.rmed.2014.05.015
11. Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy. 2008 Aug;63(8):1054-60. doi: 10.1111/j.1398-9995.2008.01672.x.
12. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age. J Allergy Clin Immunol Pract. 2018;6(2):545-554.e4. doi:10.1016/j.jaip.2017.05.032
13. Barsky EE, Giancola LM, Baxi SN, Gaffin JM. A Practical Approach to Severe Asthma in Children. Ann Am Thorac Soc. 2018;15(4):399-408. doi:10.1513/Annals ATS.201708-637FR.
14. Anderson GP. Endotyping asthma: new insights in to key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107-1119. doi:10.1016/S0140-6736(08)61452-X
15. Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649-1659. doi:10.1111/all.13771
16. Can D. Can Phenotypes be Recognized? İzmir Dr. Behçet Uz Çocuk Hast. Dergisi 2019;9(3):167-174 doi:10.5222/buchd.2019.40327.
17. Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. doi:10.1016/j.smim.2019.101301
18. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A,et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-360. doi:10.1016/j.jaci.2010.11.037
19. Pongracic JA, Krouse RZ, Babineau DC, oratti EM, Cohen RT, Wood RA, et al. Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. J Allergy Clin Immunol. 2016;138(4):1030-1041. doi:10.1016/j.jaci.2016.06.059
20. Liu AH, Babineau DC, Krouse RZ, Zoratti EM, Pongracic JA, O'Connor GT,et al. Pathways through which asthma risk factors contribute to asthma severity in inner-city children. J Allergy Clin Immunol. 2016;138(4):1042-1050. doi:10.1016/j.jaci.2016.06.060
21. Agache I, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, et al. EAACI Biologicals Guidelines - Recommendations for severe asthma [published online ahead of print, 2020 Jun 2]. Allergy. 2020;10.1111/all.14425. doi:10.1111/all.14425.
22. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017;377(10):965-976. doi:10.1056/NEJMra1608969
23. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK,et al. COVID-19, asthma, and biologic therapies: What we need to know [published online ahead of print, 2020 May 16]. World Allergy Organ J. 2020;13(5):100126. doi:10.1016/j.waojou.2020.100126
24. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respir Med. 2020;8(5):436-438. doi:10.1016/S2213-2600(20)30167-3
25. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y,et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print, 2020 Apr 12]. J Allergy Clin Immunol. 2020;S0091-6749(20)30495-4. doi:10.1016/j.jaci.2020.04.006
26. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020Weekly / April 17, 2020 / 69(15);458–464. On April 8, 2020, this report was posted online as an MMWR Early Release. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Aaccessed 23 June 2020.
27. Vultaggio A, Agache I, Akdis CA, Akdis M, Bavbek S, Bossios A,et al. Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement [published online ahead of print, 2020 Jun 5]. Allergy. 2020;10.1111/all.14407. doi:10.1111/all.14407
28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
29. Sabogal Piñeros YS, Bal SM, Dijkhuis A, Majoor CJ, Dierdorp BS, Dekker T,et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019;74(10):1898-1909. doi:10.1111/all.13802
30. COVID-19: GINA Answers to Frequently Asked Questions on asthma Management Release date: March 25, 2020 Follow GINA at @ginasthma. Available from: https://ginasthma.org/wp-content/uploads/2020/03/Final-COVID-19-answers-to-frequent-questions-25.3.2020-1.pdf. Aaccessed 23 June 2020.
31. Important information about COVID-19 for those with asthma. From the American College of Allergy, Asthma and Immunology.ARLINGTON HEIGHTS, Ill (March 12, 2020) Available from: https://acaai.org/news/important-information-about-covid-19-those-asthma. Aaccessed 23 June 2020.
32. Important information about COVID-19 for those with asthma. From the American College of Allergy, Asthma and Immunology.ARLINGTON HEIGHTS, Ill (March 12, 2020). Available from: https://acaai.org/news/important-information-about-covid-19-those-asthma. Aaccessed 23 June 2020.
33. COVID-19: information for the respiratory community. Available from: https://www.brit-thoracic.org.uk/about-us/covid-19-information-for-the-respiratory-community/. Aaccessed 23 June 2020

Severe Asthma, Bıological Treatments in Chıldren And Current Approaches In the COVID-19 Pandemic

Year 2021, Volume: 15 Issue: 2, 168 - 173, 30.03.2021

Ayşegül Ertuğrul İlknur Bostancı

https://doi.org/10.12956/tchd.758127

Cited By: 2

Abstract

Asthma is the most common chronic disease observed in children. Severe asthma is a relatively rare condition in children. As different mechanisms play role in severe asthma, there are different phenotypes and treatment should be individualized. The utilization of biological treatments to patients identified to have type 2 asthma, according to the evaluation of the factors that contribute to the patient’s asthma phenotype, has led to a significant improvement in the management of severe asthma treatment today. During the COVID-19 pandemic, current guidelines recommend continuing the biological treatments to the patients meeting biological agent usage criteria and to whom these treatments are effective. In case of active SARS‐CoV‐2 infection, biological therapy should be stopped until clinical improvement is achieved.

Keywords

severe asthma, biologicals, child, COVID-19

Project Number

YOK

References

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259. doi:10.1016/S0140-6736(17)32154-2
2. National Survey of Children's Health. NSCH 2011/12. Data query from the Child and Adolescent Health Measurement Initiative, Data Resource Center for Child and Adolescent Health website. Available from: https://www.childhealthdata.org/learn-about-the-nsch/NSCH. Aaccessed 23 June 2020.
3. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health Interview Survey, 2016. Analysis by the American Lung Association Epidemiology and Statistics Unit using SPSS software. Available from: https://www.cdc.gov/nchs/nhis/methods.htm. Aaccessed 23 June 2020.
4. Ahmed H, Turner S. Severe asthma in children-a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019;54(6):778‐787. doi:10.1002/ppul.24317
5. Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U‐BIOPRED cohorts. EurRespir J. 2015;46:1322‐1333.doi:10.1183/13993003.00780-2015
6. Selby L, Saglani S. Severe asthma in children: therapeutic considerations. Curr Opin Allergy Clin Immunol. 2019;19(2):132-140. doi:10.1097/ACI.0000000000000521
7. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013.
8. 2020 GINA Maın Report. 2020 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org/gina-reports/. Aaccessed 23 June 2020.
9. Diffucult-to-treat and severe asthma in adolescent and adult patients Diagnosis and Management. GINA 2019. Available from: https://ginasthma.org/severeasthma/. Aaccessed 23 June 2020.
10. Nordlund B, Melen E, Schultz ES, Gronlund H, Hedlin G, Kull I. Prevalence of severe childhood asthma according to the WHO. Respir Med. 2014;108:1234‐1237. doi:10.1016/j.rmed.2014.05.015
11. Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy. 2008 Aug;63(8):1054-60. doi: 10.1111/j.1398-9995.2008.01672.x.
12. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age. J Allergy Clin Immunol Pract. 2018;6(2):545-554.e4. doi:10.1016/j.jaip.2017.05.032
13. Barsky EE, Giancola LM, Baxi SN, Gaffin JM. A Practical Approach to Severe Asthma in Children. Ann Am Thorac Soc. 2018;15(4):399-408. doi:10.1513/Annals ATS.201708-637FR.
14. Anderson GP. Endotyping asthma: new insights in to key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107-1119. doi:10.1016/S0140-6736(08)61452-X
15. Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649-1659. doi:10.1111/all.13771
16. Can D. Can Phenotypes be Recognized? İzmir Dr. Behçet Uz Çocuk Hast. Dergisi 2019;9(3):167-174 doi:10.5222/buchd.2019.40327.
17. Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. doi:10.1016/j.smim.2019.101301
18. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A,et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-360. doi:10.1016/j.jaci.2010.11.037
19. Pongracic JA, Krouse RZ, Babineau DC, oratti EM, Cohen RT, Wood RA, et al. Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. J Allergy Clin Immunol. 2016;138(4):1030-1041. doi:10.1016/j.jaci.2016.06.059
20. Liu AH, Babineau DC, Krouse RZ, Zoratti EM, Pongracic JA, O'Connor GT,et al. Pathways through which asthma risk factors contribute to asthma severity in inner-city children. J Allergy Clin Immunol. 2016;138(4):1042-1050. doi:10.1016/j.jaci.2016.06.060
21. Agache I, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, et al. EAACI Biologicals Guidelines - Recommendations for severe asthma [published online ahead of print, 2020 Jun 2]. Allergy. 2020;10.1111/all.14425. doi:10.1111/all.14425.
22. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017;377(10):965-976. doi:10.1056/NEJMra1608969
23. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK,et al. COVID-19, asthma, and biologic therapies: What we need to know [published online ahead of print, 2020 May 16]. World Allergy Organ J. 2020;13(5):100126. doi:10.1016/j.waojou.2020.100126
24. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respir Med. 2020;8(5):436-438. doi:10.1016/S2213-2600(20)30167-3
25. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y,et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print, 2020 Apr 12]. J Allergy Clin Immunol. 2020;S0091-6749(20)30495-4. doi:10.1016/j.jaci.2020.04.006
26. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020Weekly / April 17, 2020 / 69(15);458–464. On April 8, 2020, this report was posted online as an MMWR Early Release. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Aaccessed 23 June 2020.
27. Vultaggio A, Agache I, Akdis CA, Akdis M, Bavbek S, Bossios A,et al. Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement [published online ahead of print, 2020 Jun 5]. Allergy. 2020;10.1111/all.14407. doi:10.1111/all.14407
28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
29. Sabogal Piñeros YS, Bal SM, Dijkhuis A, Majoor CJ, Dierdorp BS, Dekker T,et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019;74(10):1898-1909. doi:10.1111/all.13802
30. COVID-19: GINA Answers to Frequently Asked Questions on asthma Management Release date: March 25, 2020 Follow GINA at @ginasthma. Available from: https://ginasthma.org/wp-content/uploads/2020/03/Final-COVID-19-answers-to-frequent-questions-25.3.2020-1.pdf. Aaccessed 23 June 2020.
31. Important information about COVID-19 for those with asthma. From the American College of Allergy, Asthma and Immunology.ARLINGTON HEIGHTS, Ill (March 12, 2020) Available from: https://acaai.org/news/important-information-about-covid-19-those-asthma. Aaccessed 23 June 2020.
32. Important information about COVID-19 for those with asthma. From the American College of Allergy, Asthma and Immunology.ARLINGTON HEIGHTS, Ill (March 12, 2020). Available from: https://acaai.org/news/important-information-about-covid-19-those-asthma. Aaccessed 23 June 2020.
33. COVID-19: information for the respiratory community. Available from: https://www.brit-thoracic.org.uk/about-us/covid-19-information-for-the-respiratory-community/. Aaccessed 23 June 2020

There are 33 citations in total.

Details

Primary Language	Turkish
Subjects	Clinical Sciences
Journal Section	REVIEW
Authors	Ayşegül Ertuğrul 0000-0002-8146-3386 İlknur Bostancı 0000-0001-6392-5877
Project Number	YOK
Publication Date	March 30, 2021
Submission Date	June 25, 2020
Published in Issue	Year 2021 Volume: 15 Issue: 2

Cite

Vancouver	Ertuğrul A, Bostancı İ. Çocuklarda Ağır Astım, Biyolojik Tedaviler ve Covid-19 Pandemisinde Güncel Yaklaşımlar. Türkiye Çocuk Hast Derg. 2021;15(2):168-73.

Cited By

Çocuk Gelişim Kuramcılarına Göre COVID-19 Pandemisinde Okul Dönemindeki Astımlı Çocuğa Yaklaşım: Olgu Sunumu

Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi

https://doi.org/10.37989/gumussagbil.943129

Astımlı Çocuklarda COVİD-19 Pandemisi Döneminde Astım Kontrolü ve Anksiyete Düzeyinin Değerlendirilmesi

Turkish Journal of Pediatric Disease

https://doi.org/10.12956/tchd.956354

Article Files

Full Text

The publication language of Turkish Journal of Pediatric Disease is English.

Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.

The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.